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Candida albicans (C. albicans) is the micro-organism responsible for 
candidiasis, a fungal infection that may affect patients that are 
immunocompromised. This type of infection is normally treated with 
conventional anti-fungal medications such as fluconazole and clotrimazole, 
however persistent infections and treatment can lead to the development of 
anti-fungal resistance, Hydrastis canadensis L. (H. canadensis L.) and 
Calendula officinalis L. (C. officinalis L.) are medicinal plants with known 
anti-fungal effects. In vitro studies have shown that both H. canadensis 
mother tincture (Ø) and C. officinalis D1 and D3 homeopathic potencies 
have displayed inhibitory effects against C. albicans, however there has 
been no research done on the anti-fungal effects of the combination of these 
two remedies. 
The aim of this study was to determine the antimicrobial effect of H. 
canadensis and C. officinalis mother tincture complex on Candida albicans 
(C. albicans) using the Kirby-Bauer Disc Diffusion Susceptibility and Micro-
dilution method. 
The results demonstrated that the H. canadensis and C. officinalis Ø 
complex inhibited the growth of C. albicans and other Candida spp., which 
was confirmed by the Kirby-Bauer Disk Diffusion and Microdilution methods.  
H. canadensis Ø and C. officinalis Ø on their own inhibited the growth of  
C. albicans in varying degrees; however, the H. canadensis and the  
C. officinalis Ø complex displayed better anti-microbial properties than the 
C. officinalis Ø on its own, as well as the ethanol concentrations. 
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1.1 Problem Statement 
Candida albicans (C. albicans) is a yeast micro-organism that forms part of 
the commensal microbiota of the human host, however it can become 
pathogenic when the host is immunocompromised. It has the ability to adapt 
and evolve to allow for its survival (da Silva Dantas et al., 2016). This 
microorganism is responsible for candidiasis, a fungal infection typically 
causing oral or vaginal thrush, as well as invasive candidiasis, where it 
enters the bloodstream and infects organs such as the lungs, kidneys, or 
brain (Correia et al., 2019). Candidiasis has been successfully treated with 
conventional anti-fungal treatments such as fluconazole and clotrimazole, 
however, adverse effects and resistance to these treatments can occur 
(Dadar et al., 2018). This creates the need to find alternative therapies.  
Hydrastis canadensis L. (H. canadensis L.) and Calendula officinalis L.  
(C. officinalis L.) are medicinal plants with known anti-fungal effects. 
Homeopathically prepared mother tinctures (Ø) of these plants have also 
shown potential anti-fungal effects. Although research is limited, in vitro 
studies have shown that both H. canadensis Ø and C. officinalis D1 and D3 
homeopathic potencies display inhibitory effects against C. albicans 
(Budree, 2004; De Klerk, 1998). While homeopathic Ø’s are frequently 
prescribed in combination with one another in a complex, the combined 
effect of these two tinctures on C. albicans has not been previously 
explored. 
According to Yang et al. (2014), the synergistic therapeutic effects of herbal 
medicines have been frequently reported, however the exact mechanism 
by which this occurs has not been fully elucidated. The authors of this review 
propose that herbal medicines used in combination may: 1) have improved 
overall bioavailability; 2) co-operate together in a synergistic or antagonistic 
way by means of various target pathways; 3) overcome drug resistance 
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mechanisms of microbial cells; and 4) have reduced potential for producing 
adverse effects. Further research is therefore required to identify these 
synergistic effects in order to discover effective therapeutic combinations. 
1.2 Aim of the Study 
The aim of this in vitro study was to determine the effects of a homeopathic 
mother tincture complex containing H. canadensis and C. officinalis on  
C. albicans and other Candida species (spp.) using the Kirby-Bauer disc 
diffusion susceptibility and Microdilution method. 
 1.3 Objectives of the Study 
• The mother tinctures and anti-fungal control were tested using the 
Kirby Bauer method to determine the susceptibility of C. albicans to 
these compounds. 
• The minimum inhibitory concentration (MIC) for the mother tinctures 
were determined using the 96 well plate serial dilution method and 
the X-Mark Microplate Spectrophotometer (Bio-Rad; USA)  for fungal 
growth indication.  
1.4 Hypothesis 
It was hypothesised that the homeopathic mother tinctures of H. canadensis 
and C. officinalis used in combination would show antimicrobial action 
against C. albicans and other Candida spp. by demonstrating clear zones 
of inhibition. 
1.5 Null Hypothesis 
The null hypothesis states that the homeopathic mother tincture complex of 
H. canadensis and C. officinalis would not show antimicrobial action against 




1.6 Importance of the Study 
This organism was chosen since it is a common infection amongst women, 
which they treat with over-the counter fungal medication as well as other 
anti-fungals that can generate unwanted effects. C. albicans have 
developed resistance to most of these medications which makes this 




 2. LITERATURE REVIEW 
2.1 Candida species  
Candida albicans (C. albicans), Candida lusitaniae (C. lusitaniae) and 
Candida parapsilosis (C. parapsilosis) as well as other Candida strains are 
microorganisms belonging to the genus Candida. C. albicans and  
C. parapsilosis are one of the five most common candida strains whilst  
C. lusitaniae is relatively rare (Polke et al., 2015).These organisms make 
up the normal flora in the body, however a weakened immune system can 
result in opportunistic infections that affect the mucous membranes of the 
genital, urinary, respiratory, and gastrointestinal tracts, as well as the oral 
mucosa, nails, scalp, and skin. These fungal infections that are caused by 
the Candida species are known as candidiasis (de Oliveira Santos et al., 
2018). 
2.1.1 Classification, identification, and morphology of C. albicans 
C. albicans is a unicellular oval-shaped yeast that exists on mucosal 
surfaces of the body. The structure is polymorphic and asexual, and it 
develops into three distinct morphologies: hyphae, pseudo hyphae, and 
yeast. The yeast is oval, and the hyphae and pseudo hyphae are elongated, 
as per Figure 2.1. It is difficult to distinguish between the hyphae and pseudo 
hyphae as they are both filamentous forms of the fungus (da Silva Dantas 
et al., 2016). C. albicans can change its morphological state according to 
various environmental alterations. This characteristic allows for easy 
switching between the filamentous and yeast states, which enhances its 
survival (Cauchie et al., 2017).  
At ambient temperature (20–22°C), the yeast reproduces by budding, but 
at body temperature (36.5–37.5°C) they form hyphae. Pseudo hyphae form 
by budding but do not attach to adjacent tissue, thus they remain elongated. 
Alterations in the cell wall architecture and composition transform the 
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pathogen’s responsiveness to anti-fungal medication (da Silva Dantas et 
al., 2016).  
 
Figure 2. 1 Candida Morphology (Thompson et al., 2011) 
2.1.2 Pathogenesis 
The vast majority of persistent Candida infections are associated with 
biofilm development. A biofilm is defined as a microbial community that is 
embedded in a self-produced matrix of extracellular polymeric substances 
(Rafii, 2015). With biofilm development, a thin layer of microbes attaches to 
the surface of a structure and are enclosed and surrounded by an 
extracellular matrix of mucilage, enabling the microorganisms to be 
protected (Ganguly and Mitchell, 2011). As per Figure 2.2, a biofilm 
formation has four stages of growth and reaches maturation within 24 hours. 
While biofilms promote the survival of the microorganism, they are however 
responsible for persistent infections that occur in the human body, because 
of the inherent resistance of these structures to antibiotics and host defence 
systems (Kumar et al., 2017). Biofilms increase further systemic infections 
and elevate patient mortality (Rafii, 2015). Virulence factors possessed 
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by C. albicans are known to aid its biofilm-forming ability and lead to tissue 
damage and tenacity within the host (Gulati and Nobile, 2016).  
 
Figure 2. 2 Candida Biofilm Formation (Gulati and Nobile, 2016) 
C. albicans can transform from having a symbiotic relationship with the host 
to being a pathogenic infection due to its morphological switching capability 
between yeast and hyphal forms. This switching is key in its formation of 
biofilms. Morphological switching is an easily distinguishable morphological 
state of C. albicans that controls phases of colonisation, flourishing, and 
distribution. During morphogenesis, an organism changes its shape, 
triggered by factors such as temperature, serum, amino acid availability, pH 
level, and CO2 presence (Tsui et al., 2016). The yeast form has been 
associated with both initial attachment and dispersal, while the filamentous 
hyphal form enables C. albicans to invade host tissue and form a mature 
biofilm (da Silva et al., 2016). 
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 2.1.3 Predisposing factors for candidiasis 
There are several factors that predispose an individual to developing 
Candida infections. 
2.1.3.1    Predisposing conditions 
Candida infections may be triggered by underlying conditions that affect 
immune system functioning, such as the human immunodeficiency virus 
(HIV), acquired immunodeficiency syndrome (AIDS), Epstein-Barr virus, 
diabetes mellitus, and nutritional deficiencies (Pérez-García et al., 2017). 
2.1.3.2    Medications  
Antibiotics, oral glucocorticoids, and inhaled corticosteroids also put 
patients at a higher risk (Dadar et al., 2018). Corticosteroid treatment 
supresses the immune system and may decrease B-cell numbers and 
certain antibody responses (Fedor and Rubinstein, 2006). Antibiotic 
treatment eliminates the yeast's natural competitors for resources in the oral 
and intestinal flora, which increases the intensity of the condition. Hormone 
replacement therapy, infertility treatments, and cancer therapies may also 
increase the risk of contracting such infections, as do pregnancy and the 
use of oral contraceptives (Dadar et al., 2018). 
2.1.3.3    Other risk factors 
In women, the use of detergents, douches, and the presence of hormonal 
or physiological imbalances can result in disruption of the normal vaginal 
flora, causing Candida spp. overgrowth (Dadar et al., 2018). In men, penile 
candidiasis is caused by sexual intercourse with an infected partner, 




2.1.4 Infections caused by the Candida Species 
2.1.4.1    Cutaneous candidiasis 
Infections of the skin and nails present with redness, swelling, itching, and 
white exudates in the skin folds. Nail conditions include nail paronychia, 
which results in  lifting of the nail and redness and swelling around the skin. 
Superficial candidiasis in babies presents as dermatitis and swelling, 
typically affecting the genital area (Aslan Kayıran et al., 2019) 
2.1.4.2    Oropharyngeal candidiasis  
This type of infection is prevalent in HIV patients. Symptoms include a sore 
mouth, a red, burning tongue and an altered sense of taste. There are four 
types of oral candidiasis: oral thrush, erythematous candidiasis, 
hyperplastic candidiasis, and denture-induced stomatitis. Oral thrush 
presents with white, curd-like, distinct plaques on an erythematous base, 
which is revealed after the removal of the plaque. The infection can be found 
on the linings of the cheek, throat, tongue, or gums (Millsop and Fazel, 
2016). Erythematous candidiasis presents as smooth, red patches on the 
hard or soft palate, the back of the tongue, or the lining of the cheek. 
Hyperplastic candidiasis consists of white, firm patches or plaques that 
cannot be removed; these usually spread bilaterally on the lining of the 
cheek, tongue, or the hard or soft palate. Denture-induced stomatitis 
presents as either a smooth or a granular rash limited to the denture-bearing 
region of the hard palate, and is often linked to angular cheilitis, which 
presents with red, fissured lesions in the corners of the mouth (Pankhurst, 
2009). 
2.1.4.3    Vulvovaginal candidiasis 
Vulvovaginitis occurs when the Candida spp. infiltrate the mucosal lining of 
the vagina and cause inflammation and swelling. The predominant 
inflammatory cells are mostly leukocytes and macrophages. Patients may 
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have a thick and sticky discharge. They can also present with burning or 
painful urination, vaginal itching, vaginal burning, dyspareunia, and redness 
and swelling of the vagina (Jeanmonod and Jeanmonod, 2019). 
2.1.4.4    Systemic candidiasis 
This is a serious infection that can affect the blood, brain, heart, and other 
parts of the body. The most common form of systemic candidiasis is when 
the blood is infected, and this type of infection is called candidaemia. 
Patients with candidaemia present with fever and chills and do not improve 
on antibiotic treatment. Other presenting symptoms will depend on which 
organ has been infected. For example, if the heart is affected, patients could 
develop dyspnoea, and if the eyes are affected, this could result in blurry 
vision. Patients may also present with a sore throat if the oesophagus has 
been affected (Pappas et al., 2018). Systemic or invasive candidiasis is 
normally present when a patient is seriously ill and immunocompromised, 
hence some symptoms may be masked by these conditions (Nett, 2018). 
2.1.5 Conventional treatment of Candida infections 
The following anti-fungal medications are commonly used to treat 
candidiasis: azoles, which include clotrimazole and fluconazole, and 
polyenes, such as nystatin (Spampinato and Leonardi, 2013). 
2.1.5.1    Azole anti-fungals 
The azoles are the largest group of anti-fungal drugs. They consist of 
midazoles (miconazole, econazole, clotrimazole, ketoconazole), triazoles 
(fluconazole, itraconazole), voriconazole (second-generation, pseudo-
triazole derivative of fluconazole), and posaconazole (a hydroxylated 
analogue of itraconazole). Azoles are easily absorbed and usually well-
tolerated by patients (Cowen et al., 2014). These anti-fungals interfere with 
the fungal cell membrane by restricting the activity of lanosterol 14-
demethylase, which is an enzyme involved in the production of 
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ergosterol. Ergosterol is the biggest sterol portion of the fungal cell 
membrane (Spampinato and Leonardi, 2013). Fluconazole is administered 
orally and has been linked to hepatotoxicity, which is directly associated 
with dosage and duration of use, or the presence of an underlying illness. 
Other side effects of this medication may include pruritus, dry skin, and 
gastrointestinal disturbances (Kumar and Jha, 2016). Clotrimazole is 
normally administrated topically and side effects may include irritation and 
burning of the skin and, in some cases, allergic dermatitis. Re-occurrence 
of infection is possible if the course of treatment is not completed (Ahangari 
et al., 2019).  
2.1.5.2    Polyenes 
Other fungal medications such as nystatin and amphotericin B, which are 
both polyenes, bind ergosterol. This process disturbs the vital lipidic part of 
the fungal cell membrane, resulting in the manufacture of aqueous pores. 
This then leads to cellular permeability and leakage of cytosolic elements, 
resulting in fungal death (Spampinato and Leonardi, 2013). Nystatin can be 
applied topically or taken orally and is generally well-tolerated. Side effects 
could include pruritis, burning of the mucous membranes, a rash, or 
dyspnoea (Mazu et al., 2016). In contrast, amphotericin B is not well-
tolerated when taken orally, and is therefore usually administered 
intravenously. It also has a high rate of nephrotoxicity (Ellis, 2002). 
2.2 Antimicrobial resistance 
Drug resistance of Candida infections is on the increase and is a 
consequence of the widespread use of anti-fungal agents. Anti-fungal 
resistance can also occur due to decreased drug intracellular acquisition, 
reduced affinity for the drug and counteraction of the drug effect (Perlin et 
al., 2017). Biofilm production is also related to a high level of anti-fungal 
resistance, as it affects the efficacy of the antifungal medication, forming a 
physical barrier that inhibits drugs from acting on the cell (Silva et al., 2017; 
Li et al., 2018). Other factors such as efflux pumps, which are protein 
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channels that prevents the cell from accepting anti-fungal agents, add to 
biofilm anti-fungal resistance (Borghi et al., 2016). There is therefore a need 
for safer and more effective treatment options. Several medicinal plants 
have been shown to have anti-fungal properties and may provide an 
alternative treatment option for C. albicans and other Candida spp. 
infections (Soliman et al., 2017). 
2.3 Homeopathy 
2.3.1 History of homeopathy 
           Homeopathy as a discipline was founded by Dr Samuel Hahnemann in the 
19th century and is based on the principle of “like cures like.” Homeopathy 
is an alternative approach to healthcare, which looks at the patient 
holistically rather than just the symptoms with which they present (Chauhan 
and Gupta, 2012). 
2.3.2 Principles of homeopathy  
2.3.2.1    The law of similars 
The law of similars, or like cures like, is the primary law of homeopathy. It 
specifies that the symptoms of the patient do not occur because of the 
disease itself but are rather reactions of the body to that disease. Therefore, 
these symptoms need to be matched to a remedy that has been shown to 
produce a similar symptom picture in experiments called provings, which 
are conducted in healthy patients (Chauhan and Gupta, 2012). 
 2.3.2.2    Principle of the single remedy 
The principle of a single remedy states that only one remedy should be 
given at a time as remedies are proven individually. The remedy should be 
given based on its similarity to the patients’ symptoms and this remedy is 
known as the similimum (Chauhan and Gupta, 2012). 
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2.3.2.3    Principle of the minimum dose 
According to Hahnemann’s Organon, in which he described these 
fundamental principles of homeopathy, the patient should be given the 
smallest dose possible to initiate a healing response, reduce the risk of 
aggravation or harmful effects, and restore health (Chauhan and Gupta, 
2012). 
2.3.3 Homeopathic remedy manufacturing techniques 
Homeopathic remedies are made from substances derived from plant, 
mineral, and animal sources. A mother tincture (Ø) is a liquid preparation of 
a crude substance, prepared according to a standardised method as 
determined by the homeopathic pharmacopoeia (Banerjee, 1996). The 
crude material used for remedies are chopped up, diluted in distilled water 
or alcohol and left to stand for several days or weeks. Thereafter, the 
mixture is filtered to extract the liquid, which is known as the Ø. Insoluble 
crude materials are first combined with lactose and ground repeatedly to 
form a powder that is then soluble in water. This process is known as 
trituration (Malik, 2013). 
2.3.3.1    Potentisation 
Potentisation is a process of serial dilution with succussion. The succussion 
method is when the remedy is vigorously shaken to elicit its biological 
activity. To make a centesimal potency (cH), one drop of the mother tincture 
is added to 99 drops of alcohol and distilled water and succussed, and for 
decimal potencies (D or X), one drop of the mother tincture is added to nine 
drops of diluent and succussed. Subsequent potencies are made in a 





Figure 2. 3 Homeopathic Potentisation (Homeopathicassociates.com, 
2020) 
2.3.4 Mother tinctures versus herbal extracts 
Herbal extracts are prepared according to methods laid out as monographs 
found in the herbal pharmacopoeia (Vlietinck et al., 2009); these can 
include: infusions, decoctions, and percolation. The solvent-to-herb ratio 
varies according to the type of herb and the method used for extraction. The 
ratio of herb to diluent is typically 1:5, 1:10, or 1:2 (Mohammad Azmin et al., 
2016). Mother tinctures are prepared according to methods laid out in the 
homeopathic pharmacopoeia, and are in a 1:10 dilution (Lockie, 2000).  
2.4 Hydrastis canadensis L.  
Hydrastis canadensis L. (H. canadensis L.), commonly known as goldenseal, 
is shown in Figure 2.4. It is part of the Ranunculaceae family and is a 
perennial herb (Christensen and Gorchov, 2010).The root and the rhizomes 
are used in the herbal preparation for medicinal use. The main chemical 
components of H. canadensis L. are berberine, canadine, hydrastine, and 
isoquinoline alkaloids (Mandal et al., 2020). It is indicated to alleviate minor 
inflammatory conditions of the mouth, skin, and eyes as well as to treat 
diarrhoea, fever, and inflammation of vaginal and urethral mucous 
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membranes. It can also be used for urinary tract infections, liver disorders 
and pneumonia (Villinski et al., 2003).  
The main active constituent of H. canadensis L. is berberine, which is 
responsible for many of its therapeutic properties. Even though berberine 
can be obtained from other plant species such as the Berberis spp., the 
added alkaloids hydrastine and canadine in H. canadensis L. are also 
thought to be medically significant (Wallace et al., 2018). 
 
Figure 2. 4 Hydrastis Canadensis L. Rhizome (Phys.org, 2020). 
2.4.1 Hydrastis canadensis L. herbal extract 
2.4.1.1    Herbal extract preparation 
The herbal pharmacopoeia determines what the extraction, maceration, and 
herb-to-solvent ratio should be when making herbal tinctures. Herbal 
extracts of H. canadensis L. are generally prepared (British Pharmacopoeia, 
2018). 
Ultra-performance liquid chromatography (UPLC) and high-performance 
liquid chromatography (HPLC) methods are used for authentication and 
recognition of possible adulteration of H. canadensis L. and affiliated genus 
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species. These tests are performed to ensure that the plant samples contain 
the major alkaloids hydrastine and berberine (Wallace et al., 2018). 
2.4.2 Hydrastis canadensis homeopathic mother tincture 
2.4.2.1    Mother tincture preparation 
The homeopathic preparation of H. canadensis L. is known as  
H. canadensis to distinguish it from the herbal preparation. The 
homeopathic pharmacopoeia specifies the exact method required in the 
preparation of homeopathic remedies, including the collection, preparation, 
preservation, and standards thereof. Different countries use different 
pharmacopoeias. In South Africa, homeopathic remedies are usually 
prepared according to guidelines laid out in the German Homeopathic 
Pharmacopoeia (Deutscher Apotheker Verlag, 2013). 
H. canadensis mother tincture is made from the rhizome of the herb (Figure 
2.4) and prepared using the HAB4A method (Appendix B). For the 
preparation of the mother tincture, the rhizome is cleaned and finely cut. 
The cut particles are then soaked in alcohol for a few days or weeks, then 
strained and diluted (Sarembaud, 2019). 
2.4.2.2    Homeopathic indications 
In homeopathy, H. canadensis mother tincture is used as an antimicrobial, 
and it has an affinity for the mucous membranes of the body, particularly 
the throat, stomach, uterus, and urethra. It is indicated for infectious 
conditions that produce a thick, yellowish, ropy secretion, especially in the 
upper respiratory tract. It is also used to treat bacterial and fungal vaginal 
infections (Vermeulen, 2011).  
2.5 Calendula officinalis L. (C. officinalis L.) 
C. officinalis L., commonly known as marigold (see Figure 2.5), is a 
perennial herb and is part of the Asteraceae family (Shankar et al., 2017). 
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The main chemical components of this plant are carotenoids, terpenoids, 
flavonoids, coumarins, quinones, and amino acids. The carotenoids in the 
plant comprise twelve compounds, predominantly beta-carotene, lutein, 
and violaxanthin. Of these compounds, beta-carotene is the most bioactive 
(Olennikov and Kashchenko, 2014).  
This plant has been used for many years as an anti-fungal, antibacterial, 
anti-inflammatory, and antiseptic agent, useful in the treatment of wounds, 
burns, and inflammation (Abudunia et al., 2017). C. officinalis L. is used to 
treat inflamed internal organs, gastrointestinal ulcers, and dysmenorrhea. It 
is also useful as a diuretic and as a diaphoretic in seizures (Muley et al., 
2009). Other uses are for inflammation of the oral and pharyngeal mucosa, 
and for wounds and burns (Arora et al., 2013). In addition, the herb can be 
used as a detoxification agent and as a cleanser (Arora et al., 2013). The 
outcome of antimicrobial in vitro tests has shown that the Calendula genus 
displays inhibitory effects on certain fungi (Efstratiou et al., 2012). 
 
Figure 2. 5 Calendula officinalis L. plant (Lim, 2014) 
2.5.1 Calendula officinalis L. herbal extract 
2.5.1.1    Herbal extract preparation 
C. officinalis L. is recorded in the German Commission E, European 
Scientific Co‐operative on Phytotherapy, British Herbal Pharmacopoeia, 
and World Health Organization monographs for its wound healing and anti‐
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inflammatory actions (Arora et al., 2013). The flowers and leaves of the plant 
are used in the herbal preparation for medicinal use (Olennikov and 
Kashchenko, 2014); the flavonoids, glycosides, and tannins as well as other 
antioxidant compounds are responsible for its antimicrobial effects. The 
action of the tannins has been shown to oppose yeasts by crossing the cell 
wall and affecting the membrane. It then binds to the surface, which inhibits 
cell growth (Efstratiou et al., 2012) 
2.5.2 Calendula officinalis homeopathic mother tincture 
2.5.2.1    Mother tincture preparation 
Prepared C. officinalis L. in homeopathy is named C. officinalis. C. officinalis 
mother tincture is prepared according to the German Homeopathic 
Pharmacopoeia HAB3A method (Appendix B) (Deutscher Apotheker 
Verlag, 2013). It is made from the fresh flowers and leaves of the plant, that 
are finely chopped, soaked in alcohol for days or weeks, and then strained 
(Arora et al., 2013).  
2.5.2.2    Homeopathic indications 
C. officinalis mother tincture is useful in the treatment of wounds, burns, and 
septic infections of the skin and mucous membranes. It is also known as a 
homeopathic antiseptic for wound healing and prevents uncontrolled 
bleeding. It is suitable for all instances of injury where the skin is damaged, 
and it contributes to the rapid healing of wounds (Vermeulen, 2011). 
C. officinalis can be applied to affected areas to treat burns, skin conditions 
such as eczema, yeast infections, skin irritations and sunburn, and to treat 
other conditions such as varicose ulcers, postoperative wounds, and 
ruptured muscles or tendons. It is also used to treat torn perineal tissues 
following childbirth as well as joint conditions where there is loss of synovial 
fluid (Khairnar et al., 2013). 
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2.6 Related research 
While there is limited research on the effects of these two medicinal plants 
on C. albicans, there is currently no research done on the anti-fungal effects 
of the combination of these two mother tinctures. With regards to the anti-
fungal effects of H. canadensis L., the majority of research has been 
conducted on its active constituent berberine. Berberine is a protoberberine-
type isoquinoline alkaloid that has been shown to exhibit antibacterial and 
anti-fungal activity (Bone and Mills, 2013). In a study conducted by Xie et 
al. (2020) on the in vitro anti-fungal effects of berberine against Candida 
spp. in planktonic and biofilm conditions, the berberine alkaloid showed 
remarkable anti-fungal action and restrictive influence against biofilm 
formation. 
In a study by da Silva et al. (2016), the anti-fungal effect of berberine against 
multi-drug resistant Candida spp. was demonstrated. The study showed 
that berberine caused alterations to the integrity of the plasma and 
mitochondrial membranes, as well as DNA damage, which resulted in cell 
death. Berberine was also shown to produce a significant reduction in 
biofilm activity.  
In a study done by Wei et al. (2011) on the in vitro synergism between 
berberine and miconazole against planktonic and biofilm Candida cultures, 
berberine showed significant inhibition effects on the candida strains, 
including C. albicans, but the most effective inhibition was on C. krusei, 
which is a non-albicans species.  
In terms of homeopathic research,  H. canadensis mother tincture was 
shown to have inhibitory effects against the in vitro growth of C. albicans 
using the disc diffusion and broth dilution methods (Budree, 2004).  
Saffari et al. (2016) compared the effects of C. officinalis herbal extract and 
clotrimazole on vaginal candidiasis. Results showed that C. officinalis was 
effective in healing vaginal discharge, burning, and inflammation and had a 
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longer effect than clotrimazole. An in vitro study on the anti-fungal activity 
of the essential oil derived from C. officinalis L. flowers by Gazim et al. 
(2008) showed that C. albicans has sensitivity to these essential oils. 
In 1998, a study on the antimicrobial effects of C. officinalis in D1 and D3 
homeopathic dilutions on C. albicans was conducted using the disc diffusion 
and broth dilution method. The results showed that both potencies were 





 3.1 Experimental design 
This quantitative experimental research was conducted at the Water and 
Health Research Centre (WHRC) with permission granted (Appendix A) 
under the supervision of a qualified laboratory technician.  
 3.2 Candida species  
An American Type Culture Collection (ATCC 90028) reference strain of  
C. albicans was purchased and stored as per manufacturer instructions at 
the WHRC laboratory.   
Fourteen isolates of Candida spp. strains from previously analysed samples 
were included in the study to determine the effectiveness of the selected 
homeopathic tinctures on different Candida spp. strains. The selected 
strains were confirmed to be C. albicans (1)  C. lusitaniae (6),  
C. parapsilosis (5), C. guilliermondii (1), C. inconspicua/lambica (1) and  
C. rugosa (1). 
 3.3 Homeopathic remedies 
The homeopathic mother tinctures (Ø) selected to test their effectiveness 
against Candida spp. were H. canadensis Ø in 70% ethanol, C. officinalis 
Ø in 66% ethanol and a H. canadensis and C. officinalis Ø complex in 68% 
ethanol.   
3.4 Methods used for analysis 
3.4.1    Media preparation 
Brain heart infusion (BHI) broth (g/l) and Potato dextrose agar (PDA) (g/l) 
were prepared according to the manufacturer’s instructions and autoclaved 
for fifteen minutes. The Mueller Hinton broth was prepared by weighing 4.2g 
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of Mueller Hinton powder and dissolved in 200ml distilled water (dHշO). 
Mueller Hinton agar was prepared by weighing 7.6g Mueller Hinton powder, 
which was dissolved in 200ml of dHշO and poured into sterile petri dishes. 
3.4.2    Yeast culture preparation 
Fifteen yeast strains were isolated and identified using the VITEK®2 
BioMؘerieux (France) machine at the WHRC laboratory. The strains were 
stored at -80°C in glycerol and recovered by culturing in BHI broth overnight 
at 30-35°C. Growth of the yeast was identified by the turbidity of the broth 
and plated onto PDA to confirm the yeast and incubated at 30-35°C 
overnight. The plates were checked regularly for yeast growth as it could 
take up to 5 days. Once growth was observed, the isolates were gram 
stained and plated onto Mueller Hinton agar plates for the experiments and 
left overnight for fresh cultures. 
3.4.3    Preparation of Hydrastis canadensis and Calendula officinalis 
mother tinctures 
The Ø’s were purchased from a local homeopathic laboratory, Fusion 
Homoeopathics cc, who imports them from a manufacturer in Germany, 
Gehrlicher GmbH; the laboratory is able to provide certification and quality 
control documentation as proof of the medications’ quality and standard 
(Hohl, 2019). 
Fusion Homoeopathics cc made up the complex of H. canadensis and  
C. officinalis Ø in a 1:1 ratio, which was mixed together in equal parts in a 
volume-to-volume manner in a dispensing laboratory, utilising profession 
specific and general Good Dispensing Practice guidelines (Deutscher 
Apotheker Verlag, 2013). 
C. officinalis Ø was made using the HAB3A method with 66% ethanol 
concentration and H. canadensis Ø was made using the HAB4A method 
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with 70% ethanol concentration (Appendix B) (Deutscher Apotheker Verlag, 
2013). 
3.4.4    Kirby Bauer Disk Diffusion method 
The Kirby-Bauer Disk Diffusion Susceptibility method is used to measure 
the effects of antimicrobial sensitivity against various microorganisms. The 
yeast, which was grown overnight was inoculated and plated onto Mueller-
Hinton agar plates (Benkova et al., 2020). 
 The antimicrobial activity of H. canadensis and C. officinalis Ø was 
determined using the Kirby-Bauer disk diffusion method in accordance with 
the Clinical Laboratory Standards Institute (Hudzicki, 2009). 
The fifteen yeast isolates, including the C. albicans reference strain, were 
cultured, and incubated overnight at 30°C. The plates were removed from 
the incubator and allowed to reach room temperature (20°C-24°C). A 
volume of 1mL saline was aliquoted into 3mL plastic tubes, to which the 
yeast isolates were suspended individually to prepare 0.50-0.54 McFarland 
standard yeast suspensions. The Densi-check plus (bioMؘerieux) machine 
was used to confirm the McFarland standard. The individual yeast 
suspension was utilised to swab even fungal lawns onto Mueller-Hinton 
plates (Figure 3.1). The plates were allowed to settle for ten minutes at room 
temperature before applying the anti-fungal discs. 
The Mueller-Hinton Agar (MHA) used in the Kirby-Bauer technique were 
used to test the anti-microbial activity of the homeopathic mother tinctures, 





 Figure 3. 1 Fungal lawn streaking (Espinel-Ingroff, 2007) 
Sterile disks were impregnated with a range of dilutions (10ppm, 20ppm and 
25ppm) of H.  canadensis Ø, C. officinalis Ø,  a combination of  
H. canadensis and C. officinalis Ø, and ethanol in 66%, 68% and 70% as 
well Fluconazole 25mcg and blank discs were placed individually onto the 
surface of the yeast lawn agar plates using sterile forceps.  
Inoculated agar plates were inverted and incubated at 35˚C for 24 hours. 
After the incubation period, plates were examined for a zone of inhibition 
around the impregnated discs. The zones were measured from the edge of 
the disc to the outer rim of clear zone using the Automatic colony counter 
Scan® 1200 Interscience International (France) to determine if there was 
inhibition of growth. The disks used for disk diffusion had a diameter of 6 
mm therefore all measurements of <7 mm indicated that no inhibition of 
fungal growth had occurred (i.e. resistant); measurements between 8-14 
mm showed intermediate inhibition; and those >15 mm showed a sensitivity 
of the fungus to the treatment.   
The experiments were conducted in triplicate to obtain reliable results. 
Appropriate controls, such as the media (blank control), solvent (effect of 
solvent [ethanol] alone), negative (no treatment material) and positive (anti-
fungal [Fluconazole 25mcg])  were included to ensure the reliability and 
trustworthiness of the methods (Hudzicki, 2009). 
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3.4.5    Microdilution method 
The Microdilution method comprises of broth dilution procedures to 
determine the Minimum Inhibitory Concentration (MIC), which is a 
procedure that determines the lowest concentration of an antimicrobial that 
inhibits the growth of an organism and when incubated to inhibit visible 
growth. The Broth dilution utilises the 96 well plate, where the microbe is 
inoculated into a liquid medium with different concentrations of the 
antimicrobial agent (Wiegand et al., 2008). 
To determine the MIC of the tinctures, the broth dilution method was used 
whereby the compounds, as per Table 3.1, were tested using the serial 
dilution method. A 96 well plate was labelled and each well filled with 100μl 
Mueller-Hinton broth. The plate was divided into two sections and six wells 
per row used for the dilutions of each tincture, as shown in Figure 3.2. Fifty 
microliters of each compound to be tested was serially diluted by the 
addition of undiluted tincture to the first well, mixed and 50μl removed; this 
was then added to the next well and repeated for the next four wells. As per 
the Kirby Bauer method, a variety of controls were included. This consisted 
of a media control (no yeast), a media and yeast control (no antimicrobials 
added), test samples, solvent controls, and antifungal controls (positive) 
listed in the previous section. 
Table 3. 1 List of compounds added to 96 well plate 
A1-A6 Media Only A7-A12 H. canadensis + C.officinalis Ø complex 
B1-B6 Yeast Only B7-B12 H. canadensis + C.officinalis Ø complex 
C1-C6 H. canadensis Ø C7-C12 H. canadensis + C.officinalis Ø complex 
D1-C6 H. canadensis Ø D7-D12 66% ethanol 
E1-C6 H. canadensis Ø E7-E12 68% ethanol 
F1-F6 C. officinalis Ø F7-F12 70% ethanol 
G1-G6 C. officinalis Ø G7-G12 66% Fluconazole 




Figure 3. 2 A 96 well plate template for MIC dilution experiment 
A duplicate plate was prepared, and the plates were incubated at 30°C for 
18-24 hours. After the incubation period, the plates were measured for 
turbidity on the X-Mark Microplate Spectrophotometer (Bio-Rad; USA) at 
450nm, whereby the readings of growth and no growth were recorded. 
All wells that displayed no growth (clear well) and the consecutive well were 
plated onto a Mueller Hinton agar plate and incubated overnight to check if 
there was further growth; the results of this were recorded and the plates 
were incubated for a further 24 hours to check if the yeast and tincture 
reaction was fungistatic or fungicidal. 
3.5 Validity and reliability 
The Ø’s were acquired from Fusion Homeopathics cc. who imports them 
and have certified quality control measures that ensures that their products 
are of the premium quality. The study uses the Kirby-Bauer disk diffusion 
test and MIC method as recommended by the Clinical Laboratory Standards 
Institute (CLSI) (Hudzicki, 2009), and all recommended repeats and 
controls were included to ensure reliable results. All experiments were 
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performed under the supervision of a qualified laboratory technician in a 
controlled environment to ensure that the results are reliable. 
The procedure was performed in triplicate (repeatability) on three 
independent days (reproducibility) to ensure reliable results. 
H. canadensis Ø, C. officinalis Ø, H. canadensis and C. officinalis complex 
Ø along with solvent controls (66%, 68 and 70% ethanol), sterile disc control 
(distilled water), and anti-fungal control (Fluconazole 25 mcg) were included 
in each test run to ensure that the experimental conditions were correct. 
3.6 Data analysis 
Results were analysed and interpreted by the researcher with assistance 
from a statistician. Frequencies and descriptive testing were done on the 
overall sample. The Shapiro-Wilk test was utilised to test for normality and 
the Kruskal-Wallis test was performed to measure possible statistically 
significant differences among the groups. If statistically significant changes 
were noted, the Mann-Whitney comparison tests were performed to check 






The aim of the study was to investigate the antimicrobial activity of the 
homeopathic remedies H. canadensis and C. officinalis Ø complex against 
fungi, namely the Candida spp., using the Kirby-Bauer Disk Diffusion 
Susceptibility method and Microdilution method.  
The Kirby-Bauer Disk Diffusion Susceptibility method, also known as the 
Agar Disk Diffusion method, is used to test the sensitivity or resistance of 
certain microbes against antimicrobial compounds. This was the method of 
choice to test if H. canadensis and C. officinalis Ø complex could inhibit or 
kill fungal growth of the C. albicans and Candida spp. strains, respectively. 
The disks used for disk diffusion had a diameter of 6 mm therefore all 
measurements of <7 mm indicated that no inhibition of fungal growth had 
occurred (i.e. resistant); measurements between 8-14 mm showed 
intermediate inhibition; and those >15 mm showed a sensitivity of the 
fungus to the treatment.  
The minimum inhibitory concentration (MIC) of the remedies was defined 
as the lowest concentration at which fungal growth was inhibited and was 
measured using the Microdilution method.  
The Minimum Bactericidal/fungicidal Concentration (MBC/MFC) is the 
minimum concentration of a drug that is needed to kill a microbe. It is 
determined by sub-culturing broth dilutions that were shown to inhibit growth 
of a microbe in the MIC method (Wiegand et al., 2008). Mueller-Hinton agar 
plates were streaked with samples from the 96 well plates and incubated 
for 48 hours, to determine the presence of viable C. albicans cells after 




The H. canadensis Ø was prepared from the rhizome of the plant in 70% 
ethanol. The C. officinalis Ø was prepared from the fresh flowers in 66% 
ethanol and the complex of the two was prepared in 68% ethanol; these 
tinctures were purchased from Fusion Homeopathics cc, a reputable 
homeopathic laboratory who imports their tinctures from a manufacturer in 
Germany, Gehrlicher GmbH, and  can provide certification and quality 
control documentation as proof of the medications’ quality and standard 
(Hohl, 2019). 
Data was analysed and interpreted with the assistance of a statistician (De 
Klerk, 2019). Frequencies and descriptive testing were done on the overall 
sample. The Shapiro-Wilk Test was used to check for normality and showed 
an abnormal distribution of data among the samples given (owing to the 
small sample size), therefore non-parametric tests were chosen for further 
analysis.  
The Kruskal-Wallis Test is a rank-based nonparametric test used to 
determine if there are statistically significant differences between two or 
more groups of an independent variable (Pallant, 2007). If statistically 
significant differences were noted (when the p-value was < 0.05), then the 
Mann-Whitney U test was performed.  
The Mann-Whitney U test is used to compare differences between two 
independent groups when the dependent variable is either ordinal or 
continuous, but not normally distributed (Pallant, 2007).  This chapter 
summarizes and presents the data obtained from the experiments that will 
be discussed in further detail in the next chapter. 
4.2 Results for the Candida albicans strain  
4.2.1 Kirby-Bauer Disk Diffusion method 
Paper disks containing H. canadensis Ø, C. officinalis Ø, H. canadensis and  
C. officinalis Ø complex, 70% ethanol, 68% ethanol, and 66% ethanol  as 
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well as the Fluconazole anti-fungal were allowed to diffuse into the agar 
containing the C. albicans and Candida spp.  strains, thereby producing a 
clear zone around the paper disk. The zone diameters were measured and 
recorded accordingly. As shown in Figure 4.1 (A), the paper disks 
containing each of the individual tinctures, the combination of tinctures and 
the controls were placed evenly apart onto the agar. The H. canadensis Ø 
tincture produced a prominent yellow colour, as seen in disk one and disk 
three. As shown in Figure 4.1 (B), the paper disks containing (1) 
Fluconazole 25mcg and (2) the blank control were placed apart onto the 
agar, clearly showing a zone of inhibition around the anti-fungal drug and 




 Figure 4. 1 Disk diffusion agar of C. albicans (ATCC 90028) showing 
zones of inhibition for A:  Remedies (1) H. canadensis (2) C. 
officinalis, (3) H. canadensis and C. officinalis complex, (4) 
66% Ethanol, (5) 68% Ethanol and (6) 70% Ethanol and B: (1) 
Fluconazole 25mcg and (2) blank control.     
The experiments were conducted in triplicate, and a summary of the results 











inhibition were measured in millimetres (mm) and recorded for each of the 
experiments done. Values written in bold text indicate sensitivity to the 
treatment. 
The H. canadensis and C. officinalis Ø complex inhibited fungal growth of 
C. albicans with an average zone of inhibition of 17 mm. However, H. 
canadensis Ø on its own had a more notable inhibitory effect with an 
average zone of inhibition of 24 mm, while the C. officinalis Ø produced an 
average zone of inhibition of 8 mm, indicating only intermediate inhibition.  
The 66%, 68% and 70% ethanol solvents used for the preparation of the Ø 
showed fungal growth with zones of inhibition of 10 mm. The Fluconazole 
25 mcg (anti-fungal positive control) showed the highest inhibitory effect on 
C. albicans, with an average zone of inhibition of 29 mm. 
Table 4. 1 Summary of the Kirby-Bauer Disk Diffusion susceptibility test 
against C. albicans  
Sensitivity: > 15 mm; Intermediate Inhibition: 8-14 mm; Resistance: <7 mm 
 













canadensis Ø  
3 24 24 23 25 0.81 17 
C. officinalis 
Ø 





3 17 19 10 20 5.56 12 
66% ethanol 3 10 10 9 11 0.88 7 
68% ethanol 3 10 10 10 11 0.36 8 
70% ethanol 3 10 10 10 10 0.40 8 
Fluconazole 
25mcg 
3 29 29 29 29 0.00 20 
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The results for the Kruskal Wallis test are shown in Table 4.2. The results 
indicate that a statistically significant difference has occurred between the 
treatment groups (p = 0.020). 
Table 4. 2 Kruskal Wallis test statistics for the Kirby-Bauer Disk Diffusion 
test on C. albicans 
 Kruskal-Wallis H Df Asymp. Sig. 
Zone 14.975 6 0.020 
 
The results for the Mann-Whitney test for the Kirby-Bauer Disk Diffusion test 
are shown in Table 4.3. This test was used to compare treatments to see 
where the statistically significant differences occurred. Statistically 
significant results are in bold and are indicated by p values less than 0.050.  
Table 4. 3 The Mann- Whitney U test statistics for the Kirby-Bauer Disk 
Diffusion on C. albicans 
Treatment 1 Treatment 2 p-value 
H. canadensis Ø C. officinalis Ø 0.050 
H. canadensis Ø H. canadensis & C. officinalis Ø 
complex 
0.050 
H. canadensis Ø 66 % ethanol 0.050 
H. canadensis Ø 68% ethanol 0.050 
H. canadensis Ø 70% ethanol 0.046 
H. canadensis Ø Fluconazole 25mcg 0.037 
C. officinalis Ø H. canadensis & C. officinalis Ø 
complex 
0.127 
C. officinalis Ø 66 % ethanol 0.275 
C. officinalis Ø 68% ethanol 0.513 
C. officinalis Ø 70% ethanol 0.507 
C. officinalis Ø Fluconazole 25mcg 0.037 
H. canadensis &  
C. officinalis Ø complex 




Table 4.3 continued  The Mann-Whiitney U test statistics for the Kirby-
Bauer Disk Diffusion on C. albicans. 
Treatment 1 Treatment 2 p-value 
H. canadensis &  
C. officinalis Ø complex 
68% ethanol 0.127 
H. canadensis &  
C. officinalis Ø complex 
70% ethanol 0.268 
H. canadensis &  
C. officinalis Ø complex 
Fluconazole 25mcg 0.037 
66% ethanol 68% ethanol 0.513 
66% ethanol 70% ethanol 0.507 
66% ethanol Fluconazole 25mcg 0.037 
68% ethanol 70% ethanol 0.825 
68% ethanol Fluconazole 25mcg 0.037 
70% ethanol Fluconazole 25mcg 0.034 
 
According to these results, Fluconazole significantly outperformed the H. 
canadensis Ø, the C, officinalis Ø, the H. canadensis and C. officinalis Ø 
complex, as well as the 66%, 68% and 70% ethanol samples. 
4.2.2 Microdilution method 
The minimum tincture concentration required for inhibition of yeast growth 
was tested by the serial dilution method in 96 well plates, as shown in Figure 
4.2. The absorbance readings (OD 450nm) were used to determine the 
effectiveness of the tinctures against the yeast. Inhibition of growth was 
determined by calculating the difference in the pre- and post- incubation 
absorbance of wells. A reduction in the corrected absorbance, highlighted 
by a negative value or a value less than the yeast absorbance value (0.37 




Figure 4. 2 96 well plate for MIC dilution of C. albicans (ATCC 90028) 
The data for the MIC, as shown in Table 4.4, below confirmed that 
H.canadensis and C. officinalis Ø complex and C. officinalis Ø had positive 
anti-fungal effects against C. albicans. H.canadensis Ø had a higher 
absorbance reading than the yeast but it could be due to the residue in the 
tincture that influenced the reading.  The p-values <0.050 shows statistically 
difference between the treatments, however these had none. 













H. canadensis Ø 0.46 0.15 2 0 0.60 19 
C. officinalis Ø 0.22 0.23 0 0 0.07 18 
H. canadensis & C. 
officinalis Ø complex 
0.06 0.09 0 0 0.24 12 
66% ethanol 0.29 0.31 0 0 0.09 29 
68% ethanol 0.24 0.26 0 0 0.09 24 
70% ethanol 0.29 0.28 0 0 0.03 30 




The results for the Kruskal Wallis test are shown in Table 4.5. The results 
indicate that a statistically significant difference did not occur between the 
treatment groups (p = 0.123), therefore the Mann-Whitney test was not 
performed. 
Table 4. 5 Kruskal Wallis test statistics for the Microdilution test on  
C. albicans 
 Kruskal-Wallis H Df Asymp. Sig. 
Zone 10.041 6 0.123 
The first wells of the two Ø’s, which had the highest concentration of the 
tinctures, showed growth visually as the wells were cloudy and had residue 
in it, however it cannot be established whether the turbidity was due to the 
settling of the residue of the tinctures itself or from growth of the yeast. The 
wells thereafter showed no growth.  The first well had a dry residue 
concentration of 0.40 m/m, as per Table 4.6 below, however, the C. 
officinalis Ø and the Ø complex did not have any residue settling and did 
not seem to affect the absorbance readings.  
The exact concentration of the dry residue for the tinctures is not known. 
The percentage (m/m) dry residue concentration was given by the supplier 
(Appendices C and D). This was to determine a MIC related to the mass 
plant extract prepared according to the method HAB4A (H. canadensis Ø), 
HAB3A(C. officinalis Ø)(Appendix B), as described in the German 
Homeopathic Pharmacopoeia (Deutscher Apotheker Verlag, 2013). The 
concentration after dilution was calculated using the following equation: 
𝐶𝐶2 =𝐶𝐶1 × 𝑉𝑉1 
          𝑉𝑉2 
Where C1 is the starting concentration given as % m/m dry residue 
C2 is the % m/m dry residue concentration after dilution 
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V1 is the volume of C1 added 
V2 is the final volume after addition of V1 to the well 
Table 4. 6 The percentage of dry residue concentration in each well for 
the homeopathic Ø’s 












Well 5  
32x 




1.2 0.40 0.13 0.04 0.02 0.01 0.00 
C. officinalis Ø 1.7 0.57 0.19 0.06 0.02 0.01 0.00 
H. canadensis 
& C. officinalis 
Ø Complex 
1.45 0.48 0.16 0.05 0.02 0.01 0.00 
The corrected absorbance readings, as per Table 4.7, showed that the 
highest concentration of H. canadensis Ø at the first well had a higher 
absorbance reading compared to the H. canadensis and C. officinalis Ø 
complex. The absorbance decreased as the H. canadensis Ø was diluted, 
however for the C. officinalis Ø, H. canadensis and C. officinalis Ø complex, 
ethanol concentrations (66%, 68% and 70%) and Fluconazole, the 
absorbance readings increased as the concentrations of the compounds 
decreased. The increased absorbance is consistent with the growth of yeast 
during the incubation period. The Fluconazole displayed inhibition until the 
32x dilution, which demonstrates the directly proportionate relationship 
between concentration and growth inhibition. The values in bold are lower 




Table 4. 7 Summary of the results for the 2-fold dilution series for  
C. albicans 
Dilutions in nm 2x 4x 8x 16x 32x 64x 
Isolate: C. albicans       
Blank -0.01 -0.01 -0.01 0.00 -0.00 -0.00 
Yeast only 0.37 0.37 0.36 0.34 0.35 0.36 
H. canadensis Ø 1.55 0.81 0.08 0.04 0.11 0.20 
C. officinalis Ø 0.09 0.24 0.21 0.23 0.25 0.28 
H. Canadensis/ 
Calendula officinalis Ø complex 
-0.39 0.25 0.05 0.05 0.14 0.29 
66% Ethanol 0.14 0.24 0.28 0.34 0.36 0.38 
68% Ethanol 0.25 0.27 0.51 0.52 0.54 0.67 
70% Ethanol 0.28 0.26 0.27 0.30 0.32 0.34 
Fluconazole 0.14 0.12 0.14 0.21 0.30 0.38 
 
4.2.3 Minimum Fungicidal Concentration Method (MFC) 
The MFC test was performed to check if there was fungal inhibition or fungal 
death in the wells that showed no growth. These were visually checked in 
the 96 well plates and the first well that showed no growth was plated onto 
the Mueller Hinton agar plate, as per Figure 4.3 below, and incubated for 
24 hours. The results after 24hrs showed that there was growth on the agar 





Figure 4. 3 Agar plate of MFC method for C. albicans A: Agar plate reading 
showing clear growth after 24 hours B: Grid plate showing wells 
that were plated on agar plate 
Table 4. 8 List of compounds on grid plate 
A1-6 Media only A7-12 H. canadensis & C. officinalis Ø 
complex 
B1-6 Media & Yeast B7-12 H. canadensis & C. officinalis Ø 
complex 
C1-6 H.  canadensis Ø C7-12 H. canadensis & C. officinalis Ø 
complex 
D1-6 H.  canadensis Ø D7-12 66% EtOH 
E1-6 H.  canadensis Ø E7-12 68% EtOH 
F1-6 C. officinalis Ø F7-12 70% EtOH 
G1-6 C. officinalis Ø G7-12 Fluconazole 25mcg 
H1-6 C. officinalis Ø H7-12 Blank 
 
4.3 Results for emerging pathogenic Candida spp. strains 
The other five Candida spp. strains that were tested included: C. lusitaniae 
(n=6) and C. parapsilosis (n=5), C. guilliermondii (n=1),  
C. inconspicua/lambica (n=1) and C. rugosa (n=1). The number in brackets 




which are also are responsible for candidiasis, and with growing resistance 
to anti-fungal medications such as Fluconazole (Mixão et al., 2019; 
Arendrup, 2013). The strains tested were all obtained from human samples. 
Statistical analysis was not done on these strains as the focus of the study 
was on C. albicans. 
4.3.1 Kirby-Bauer Disk Diffusion method 
A summary of the average zones of inhibition for all the Candida species 
strains analysed is presented in Table 4.9. Measurements are rounded off 
to the nearest decimal. 
4.3.1.1     C. lusitaniae 
In Figure 4.4, the zone of inhibition is indicated by the clear region 
surrounding the paper disk. C. lusitaniae growth is observed by the white 
lawn beyond the zone of inhibition.  
 
Figure 4. 4 Disk diffusion agar of C. lusitaniae showing zones of inhibition 
for A: Remedies (1) H. canadensis (2) C. officinalis, (3) H. 
canadensis and C. officinalis complex , (4) 66% Ethanol, (5) 
68% Ethanol and (6) 70% Ethanol and B: (1) Fluconazole 
















The H. canadensis and C. officinalis complex Ø inhibited fungal growth of 
C. lusitaniae with an average zone of inhibition of 19 mm, but H. canadensis 
Ø on its own had a more notable inhibitory effect with an average zone of 
inhibition of 23 mm, which shows that the microbe is sensitive to the tincture. 
The C. officinalis Ø had an average zone of inhibition of only 10 mm. The 
66%, 68% and 70% ethanol solvents used for the preparation of the Ø’s 
showed fungal growth with zones of inhibition of 9 mm, 10 mm, and 9 mm, 
respectively. The Fluconazole 25 mcg showed the highest inhibitory effect 
on C. lusitaniae, with an average zone of inhibition of 36 mm. 
4.3.1.2    C. parapsilosis 
Figure 4.5 highlights the effects of the tinctures on C. parapsilosis, indicated 
by the zones of inhibition surrounding the impregnated disks.  
 
 
Figure 4. 5 Disk diffusion agar of C. parapsilosis showing zones of 
inhibition for A: Remedies (1) H. canadensis (2) C. officinalis, 
(3) H. canadensis and C. officinalis complex, (4) 66% Ethanol, 
(5) 68% Ethanol and (6) 70% Ethanol and B: (1) Fluconazole 
















The H. canadensis and C. officinalis complex Ø inhibited the fungal growth 
of C. parapsilosis with an average zone of inhibition of 35 mm and had the 
same effect as H. canadensis Ø on its own. The C. officinalis Ø produced 
an average zone of inhibition of only 10 mm. The 66%, 68% and 70% 
ethanol solvents used for the preparation of the Ø showed fungal growth 
with equal zones of inhibition of 9 mm. The Fluconazole 25 mcg showed the 
highest inhibitory effect on C. parapsilosis with an average zone of inhibition 
of 47 mm. 
4.3.1.3    C. guilliermondii 
Figure 4.6 highlights the effects of the tinctures on C. guilliermondii, 












Figure 4. 6 Disk diffusion agar of C. guilliermondii showing zones of 
inhibition for A: Remedies (1) H. canadensis (2) C. officinalis, 
(3) H. canadensis and C. officinalis complex, (4) 66% 
Ethanol, (5) 68% Ethanol and (6) 70% Ethanol and B: (1) 












The H. canadensis and C. officinalis complex Ø inhibited fungal growth of  
C.  guilliermondii with an average zone of inhibition of 8 mm, but H. 
canadensis on its own had a more prominent inhibitory effect with an 
average zone of inhibition of 11 mm, which indicates intermediate inhibition. 
The C. officinalis Ø had an average zone of inhibition of 8 mm. The 66%, 
68% and 70% ethanol solvents used for the preparation of the Ø showed 
fungal growth with equal zones of inhibition of 8 mm and 7 mm, respectively. 
The Fluconazole 25 mcg showed the highest inhibitory effect on  
C. guilliermondii with an average zone of inhibition of 22 mm. 
 
4.3.1.4    C. inconspicua/lambica 
 
Figure 4.7 highlights the effects of the tinctures on C. inconspicua/lambica, 













Figure 4. 7 Disk diffusion agar of C. inconspicua/lambica showing zones of 
inhibition for A: Remedies (1) H. canadensis (2) C. officinalis, 
(3) H. canadensis and C. officinalis complex, (4) 66% Ethanol, 











The H. canadensis and C. officinalis complex Ø inhibited fungal growth of  
C.  inconspicua/lambica with an average zone of inhibition of 6 mm, as did 
H. canadensis Ø and the C. officinalis Ø, showing that the strain is resistant. 
The 66%, 68% and 70% ethanol solvents used for the preparation of the Ø 
showed fungal growth with zones of inhibition of 6 mm, respectively. The 
Fluconazole 25mcg also showed an inhibitory effect on  
C. inconspicua/lambica with an average zone of inhibition of 6 mm. This 
whole plate had an average of 6 mm, showing that this strain is resistant 
and therefore the Ø’s and the anti-fungal were ineffective.  
4.3.1.5    C. rugosa 
Figure 4.8 highlights the effects of the tinctures on C. rugosa, indicated by 













Figure 4. 8 Disk diffusion agar of C. rugosa showing zones of inhibition for 
A: Remedies (1) H. canadensis (2) C. officinalis, (3) H. 
canadensis and C. officinalis complex, (4) 66% Ethanol, (5) 
68% Ethanol and (6) 70% Ethanol and B: (1) Fluconazole 












The H. canadensis and C. officinalis Ø complex inhibited fungal growth of 
C. rugosa with an average zone of inhibition of 17 mm, which was the same 
inhibitory effect as H. canadensis with an average zone of inhibition of 17 
mm. The C. officinalis Ø had an average zone of inhibition of only 7 mm. 
The 66% ,68% and 70% ethanol solvents used for the preparation of the Ø 
showed fungal growth with zones of inhibition of 6 mm, respectively. The 
Fluconazole 25 mcg showed a prominent effect on C. rugosa with an 
average zone of inhibition of 28 mm. 
Table 4. 9 Summary of the Kirby-Bauer Disk Diffusion susceptibility test 












































































C. albicans ATCC 
90028  
24 8 17 10 10 10 29 
C. lusitaniae  23 10 19 9 10 9 36 
C. parapsilosis 35 10 35 9 9 9 47 
C. guilliermondii Human 
 





6 6 6 6 6 6 6 
C. rugosa Human 
 
17 7 17 6 6 6 28 
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Sensitive: >15 mm; Intermediate: 8-14 mm; Resistance: <7 mm 
 
4.3.2 Microdilution method 
The results from the Microdilution method to determine the MIC, presented 
in Table 4.10, show that H. canadensis Ø, H. canadensis and C. officinalis 
Ø complex, as well as C. officinalis Ø exhibited inhibition against Candida 
spp. which included C. lusitaniae (6) and C. parapsilosis (5),  
C. guilliermondii (1), C. inconspic/lambica (1) and C. rugosa (1). Values 
highlighted in bold indicate values less than the yeast value, which show 
inhibition of the strain.  The yeast value ranged from 0.46 nm in 2x dilution 
and until 0.37 nm in the 64x dilution.  
Table 4. 10 Summary of the results for the 2-fold Microdilution method for 
Candida spp. 
Dilutions in nm 2x 4x 8x 16x 32x 64x 
Isolate: C. lusitaniae 
Blank 0.00 0.00 -0.00 -0.00 -0.00 -0.00 
Yeast only 0.48 0.46 0.35 0.33 0.37 0.41 
H. canadensis Ø -0.94 0.01 0.08 0.10 0.22 0.32 
C. officinalis Ø 0.14 0.28 0.29 0.28 0.31 0.36 
H. Canadensis/ 
Calendula officinalis Ø complex 
-0.40 -0.00 0.08 0.14 0.29 0.41 
66% Ethanol 0.27 0.38 0.40 0.41 0.42 0.43 
68% Ethanol 0.26 0.36 0.41 0.41 0.42 0.41 
70% Ethanol 0.27 0.35 0.38 0.39 0.40 0.40 
Fluconazole 0.16 0.18 0.24 0.38 0.40 0.42 
 
Isolate: C. parapsilosis 
Blank 0.01 -0.00 0.00 0.07 -0.00 -0.00 
Yeast only 0.46 0.46 0.43 0.42 0.43 0.43 
H. canadensis Ø -0.68 -0.10 0.00 0.05 0.21 0.24 
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C. officinalis  Ø 0.03 0.14 0.17 0.19 0.25 0.30 
Table 4.10 continued  Summary of the results for the 2-fold Microdilution 
method for Candida spp. 
Dilutions in nm 2x 4x 8x 16x 32x 64x 
H. Canadensis/ 
Calendula officinalis Ø complex 
-0.85 -0.05 0.04 0.10 0.22 0.30 
66% Ethanol 0.35 0.37 0.39 0.41 0.42 0.47 
68% Ethanol 0.35 0.35 0.38 0.39 0.42 0.49 
70% Ethanol 0.28 0.36 0.34 0.37 0.41 0.45 
Fluconazole 0.22 0.24 0.27 0.32 0.36 0.46 
 
Isolate: C. guilliermondii 
Blank 0.00 0.00 0.00 -0.01 -0.01 -0.00 
Yeast only 0.61 0.66 0.64 0.64 0.64 0.59 
H. canadensis Ø -0.83 0.03 0.09 0.13 0.32 0.41 
C. officinalis  Ø 0.11 0.19 0.14 0.23 0.34 0.67 
H. Canadensis/ 
Calendula officinalis Ø complex 
-0.26 0.10 0.14 0.22 0.50 0.64 
66% Ethanol 0.14 0.46 0.47 0.56 0.58 0.78 
68% Ethanol 0.15 0.43 0.51 0.52 0.54 0.67 
70% Ethanol 0.19 0.34 0.47 0.55 0.55 0.64 
Fluconazole 0.63 0.79 0.78 0.67 0.58 0.59 
 
Isolate: C. inconspicua/lambica 
Blank 0.00 0.00 0.00 0.00 0.00 0.25 
Yeast only 1.29 1.26 1.27 1.26 1.22 1.16 
H. canadensis Ø 0.57 1.05 1.42 1.20 1.20 1.10 
C. officinalis  Ø 1.37 1.09 1.20 1.16 1.22 1.25 
H. Canadensis/ 
Calendula officinalis Ø complex 
1.04 0.77 1.21 1.24 1.25 1.27 
66% Ethanol 0.48 1.02 1.25 1.25 1.25 1.30 
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68% Ethanol 0.86 1.10 1.27 1.25 1.28 1.33 
Table 4.10 continued  Summary of the results for the 2-fold Microdilution 
method for Candida spp. 
Dilutions in nm 2x 4x 8x 16x 32x 64x 
70% Ethanol 1.02 1.20 1.27 1.27 1.29 1.33 
Fluconazole 1.19 1.27 1.28 1.28 1.28 1.31 
 
Isolate: C. rugosa 
Blank 0.01 -0.00 -0.00 -0.00 -0.00 -0.00 
Yeast only 0.43 0.47 0.36 0.21 0.29 0.37 
H. canadensis Ø 0.06 0.39 0.23 0.16 0.15 0.28 
C. officinalis  Ø 0.08 0.04 0.04 0.09 0.25 0.35 
H. Canadensis/ 
Calendula officinalis Ø complex 
0.12 -0.03 0.08 0.21 0.21 0.28 
66% Ethanol 0.05 0.34 0.42 0.38 0.35 0.31 
68% Ethanol 0.10 0.34 0.41 0.44 0.38 0.37 
70% Ethanol 0.13 0.34 0.36 0.44 0.35 0.41 
Fluconazole 0.18 0.30 0.34 0.40 0.32 0.42 
 
As stated above, a reduction in the corrected absorbance reading 
highlighted by a negative value or a value less than the yeast absorbance 
value indicated inhibition of yeast growth. The corrected absorbance 
readings for the six strains tested of C. lusitaniae, as per Table 4.10, showed 
that the 2-fold dilution concentration of H. canadensis Ø had a lower 
absorbance reading of -0.94 nm compared to the H. canadensis and  
C. officinalis Ø complex with a reading of -0.40 nm. The absorbance reading 
increased as the H. canadensis Ø and the Ø complex were diluted, with the 
last well having readings of 0.32 and 0.41 nm, respectively. The same was 
evident for the C. officinalis Ø, ethanol concentrations (66%, 68% and 70%) 
and Fluconazole, where the absorbance readings increased as the 
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concentration of the compounds decreased. The increased absorbance is 
consistent with the growth of yeast during the incubation period. 
The absorbance readings of the five strains of C. parapsilosis tested 
showed that the H. canadensis and C. officinalis Ø complex had lower 
absorbance readings of -0.85 nm than the H. canadensis Ø with a reading 
of -0.68 nm; the absorbance readings increased as the tinctures were 
diluted and the last well had readings of 0.30 nm for the complex and 0.24 
nm for H. canadensis. The C. officinalis Ø had an initial absorbance reading 
of 0.03 nm and increased with a last well reading of 0.30 nm, the same as 
the Ø complex. With regards to the ethanol concentrations (66%, 68% and 
70%) and Fluconazole, the absorbance readings increased as the 
concentrations of the compounds decreased, however the readings in the 
last well at the 64x dilution were all above the yeast value of 0.43 nm 
indicating that there was no effect on the compound. 
The results for C. guilliermondii, as per the data in Table 4.10, demonstrated 
that the H. canadensis Ø, C. officinalis Ø and the Ø complex all had lower 
absorbance readings in the first well and steadily increased as the tinctures 
were diluted. The first well had readings of -0.83 nm, 0.11 nm, and -0.26 
nm, respectively for the three tinctures. The ethanol concentrations of 66%, 
68% and 70% also had lower initial absorbance readings and these 
increased, however the last well readings of 0.78 nm, 0.67 nm and 0.64 nm 
respectively were higher than the last well value of 0.59 nm, which shows 
that the ethanol had no effect at this dilution. The strain showed resistance 
to the anti-fungal as the values were the same as the yeast value at the last 
well, with a reading of 0.59 nm. 
The C. inconspicua/lambica strain showed lower absorbance readings for 
H. canadensis Ø and the ethanol concentrations of 66% and 68%, with 
readings of 0.57 nm, 0.48 nm and 0.86 nm respectively; these increased as 
the tincture was diluted, however  C. officinalis Ø appeared to have initial 
resistance with a higher absorbance reading of 1.37 nm and the readings 
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decreased until the 32x dilution, where it remained the same as the yeast 
value, showing that it had no effect. The Ø complex had lower absorbance 
readings until the 16x dilution and thereafter it had higher readings than the 
yeast, showing that the lower dilution was not effective on this strain. The 
70% ethanol had a lower absorbance reading in the first two wells but 
increased thereafter and was higher than the yeast absorbance reading. 
This indicates that this strain exhibited resistance to the 70% ethanol.  The 
anti-fungal had a lower absorbance reading than the yeast in the first well 
only and as the treatment was diluted it showed higher values than the 
yeast, also indicating resistance of this strain to the Fluconazole treatment. 
C. rugosa corrected absorbance readings, as per Table 4.10, showed that 
the highest concentration of H. canadensis Ø at the first well had a lower 
absorbance reading of 0.06 nm compared to the H. canadensis and  
C. officinalis Ø complex reading of 0.12 nm. The absorbance increased as 
the H. canadensis Ø was diluted. This was also evident in the readings for 
the C. officinalis Ø, H. canadensis and C. officinalis Ø complex, the ethanol 
concentrations (66%, 68% and 70%) and Fluconazole, where the 
absorbance readings increased as the concentrations of the compounds 
decreased. The increased absorbance is consistent with the growth of yeast 
during the incubation period. The Fluconazole displayed inhibition only at 
the 2x dilution which demonstrates resistance of this strain to the anti-
fungal.  
4.3.3 Minimum fungicidal concentration (MFC) method 
Figure 4.9 below shows Mueller-Hinton agar plates that were streaked with 
cells from the wells in Figure 4.2 to confirm the presence of viable Candida 
spp. cells after treatment with the H. canadensis Ø, C. officinalis Ø and the 
complex of the two (Table 4.11). 
These were visually checked in the 96 well plates and the first well that 
showed no growth was plated onto a Mueller Hinton agar plate, as per 
Figure 4.9, and incubated for 24 hours. These were then checked and 
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thereafter incubated for another 24hrs for a total of 48 hrs. The plate below 
clearly shows fungal inhibition and not fungal death due to the regrowth, 
and this was evident for all the Candida spp. strains tested. 
  
Figure 4. 9  Agar plate of MFC method of Candida spp. A: Agar plate 
reading showing clear growth after 24 hours  B: Grid plate 
showing wells that were plated on agar plate.  
Table 4. 11 List of compounds on grid plate 
A1-6 Media only A7-12 H. canadensis & C. officinalis Ø 
complex 
B1-6 Media & Yeast B7-12 H. canadensis & C. officinalis Ø 
complex 
C1-6 H. canadensis Ø C7-12 H. canadensis & C. officinalis Ø 
complex 
D1-6 H. canadensis Ø D7-12 66% EtOH 
E1-6 H. canadensis Ø E7-12 68% EtOH 
F1-6 C. officinalis Ø F7-12 70% EtOH 
G1-6 C. officinalis Ø G7-12 Fluconazole 25mcg 
H1-6 C. officinalis Ø H7-12 Blank 
 
 
5. DISCUSSION OF RESULTS 
The antimicrobial effects of the homeopathic Ø’s H. canadensis and  
C. officinalis complex on C. albicans and other Candida spp., are discussed 
below as per the results produced by the Kirby-Bauer Disk Diffusion Method 
and Microdilution method. 
5.1 Discussion of experimental results for C. albicans 
5.1.1    Kirby-Bauer Disk Diffusion Method 
The anti-fungal effect of the homeopathic Ø’s were determined by 
evaluating which Ø’s inhibited the growth of C. albicans and other strains of 
the Candida spp. The disks used for disk diffusion had a diameter of 6 mm, 
therefore all measurements of <7 mm indicated that no inhibition of fungal 
growth had occurred (i.e., resistant); measurements between 8-14 mm 
showed intermediate inhibition, and those >15 mm showed sensitivity of the 
fungus to the treatment. 
The zone of inhibition for each disk was measured in millimetres (in triplicate 
for accuracy). The average measurement was calculated and used as the 
measurement of the zone of inhibition, as per Table 4.1. 
According to these results, H. canadensis Ø had an average measurement 
of 24 mm for C. albicans, which shows that the yeast was sensitive to the 
treatment. The three ethanol concentrations produced a zone of inhibition 
of growth of only 10 mm each, which shows that the alcohol itself is not 
wholly responsible for the antifungal effects of the tinctures. Interestingly 
though, C. officinalis Ø produced a zone of inhibition of growth of 8 mm on 
C. albicans, which was less than the ethanol concentration of 66% in which 
it was prepared in, which produced a zone of 10 mm.  
The complex of H. canadensis Ø and C. officinalis Ø had a zone of inhibition 
of growth of 17 mm, which was greater than the zone produced by the 68% 
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ethanol concentration (10 mm) in which it was prepared in; however, still 
less than that produced by H. canadensis Ø alone. Both H. canadensis Ø 
and the Ø complex displayed >15 mm zones of inhibition towards  
C. albicans, which indicates that the yeast was sensitive to the treatment. 
The anti-fungal Fluconazole 25mcg produced the largest zone of inhibition 
on all three plates with an average of 29 mm, which indicates that the strain 
was sensitive to the anti-fungal treatment. 
Overall, the results show that H. canadensis Ø and Fluconazole 25mcg had 
the highest inhibitory effect on the C. albicans strain, whilst the Ø complex 
also showed a notable effect; this result indicates that the C. albicans strain 
exhibits a sensitivity to these mother tinctures.  C. officinalis Ø on its own 
and the ethanol concentrations of 66%, 68% and 70% produced 
intermediate effects on the C. albicans strain. 
The Kruskal Wallis test revealed that a statistically significant difference 
occurred between the treatment groups (p = 0.020). The Mann-Whitney test 
was then used to determine where these statistically significant differences 
occurred. The results showed that the Fluconazole significantly 
outperformed the H. canadensis Ø, the C. officinalis Ø, and the  
H. canadensis and C. officinalis Ø complex, as well as the 66%, 68% and 
70% ethanol samples. It also showed that the 70% ethanol outperformed 
the H. canadensis Ø. 
5.1.2    Microdilution method 
The Microdilution method was used to confirm the results obtained from the 
Kirby-Bauer Disk Diffusion Susceptibility test, and to determine the MIC. 
Table 4.4 shows a summary of MIC of the H. canadensis Ø, C. officinalis Ø 
and the H. canadensis Ø plus C. officinalis Ø complex. The OD readings 
showed the differences between the various wells for the tinctures, 
Fluconazole, the three ethanol concentrations, as well as the wells that 
contained the media and yeast only as a control.  
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H. canadensis Ø showed fungal inhibition at the third well (8x dilution), with 
an OD reading of 0.08 nm. The untreated yeast cells in the 8x dilution had 
an OD reading of 0.36nm; thus, the inhibitory effect of H. canadensis Ø is 
observed by the drastic OD reduction. The inhibition was observed for all 
dilutions, thereafter, confirming the effectiveness of H. canadensis Ø 
against C. albicans.  An observed phenomenon for the H. canadensis Ø 
was the increased yeast growth at the higher concentrations of the tincture. 
It was expected to have minimal yeast growth at the higher concentrations; 
however, the tincture displayed inhibitory effects at lower dilutions instead. 
This can possibly be explained according to the homeopathic law of serial 
dilutions and minimum dose, whereby the smallest dose given can bring 
about cure. Mother tinctures are unprocessed materials that are mixed with 
alcohol and are the starting process of all homeopathic preparations; in 
homeopathy this is known as the lowest potency but with the highest 
concentration of active ingredients. Samuel Hahnemann formulated a 
process called potentisation to reduce the dose of the remedy by diluting it. 
This process enables the homeopathic potency drug to work by enhancing 
its dynamic properties (Chauhan and Gupta, 2012). This phenomenon did 
not however occur with the C. officinalis Ø or the complex, and it is not yet 
known why this only occurred with the H. canadensis Ø.    
The MIC readings for C. officinalis Ø confirmed the inhibition of yeast growth 
for the dilution range. The highest level of inhibition was noted at the most 
concentrated.  
C. officinalis Ø in well one (2x dilution), with an OD value of 0.09 nm. The 
analysis showed an average MIC value irrespective of the dilution factor of 
0.22 nm, which is below the OD value 0.30 nm for the yeast control.    
The combination of H. canadensis Ø and C. officinalis Ø complex 
demonstrated the lowest OD value of -0.39nm for all tinctures tested. This 
was reiterated with a mean value of 0.06 nm; thus, indicating the 
effectiveness of the tincture complex against C. albicans for the 
Microdilution method. Interestingly, the OD value increased to 0.25 nm at 
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the second well (4x dilution); thereafter the values decreased to 0.05 nm for 
the subsequent dilutions. This pattern may be a result of either human error 
during the preparation of the MIC plates or it is as a result of the phenomena 
observed for H. canadensis Ø. 
The average MIC values for the ethanol controls were 0.29 nm for 66% and 
70% ethanol, and 0.24 nm for the 68% ethanol. This data showed that the 
ethanol had some level of inhibition against C. albicans. The inhibitory effect 
of the ethanol controls on C. albicans were reduced as they were further 
diluted.  
The Fluconazole had an OD value of 0.14 nm at the highest concentration, 
with an increasing OD value as the anti-fungal was diluted. The most diluted 
Fluconazole concentration had an OD of 0.38 nm. The value was indicative 
of the reduced inhibitory effect of Fluconazole against C. albicans when 
diluted 64-fold. The value increased as the dilutions increased; however, 
this reading was higher than the yeast reading of 0.36. 
5.1.3 Minimum Fungicidal Method (MFC) 
This method was used to check whether the tinctures, ethanol and anti-
fungal compounds used in the 96 wells were fungicidal or fungistatic. From 
the MFC analysis, it was noted that all the tinctures had a fungistatic 
(suppressed growth) effect rather than a fungicidal (killed) effect. The 
recovery of the yeast cells, when given nutrients, enabled them to grow and 
flourish after the incubation period, which confirmed the fungistatic 
mechanism of the tinctures. To determine the fungicidal levels of the 
tinctures, further dose experiments need to be conducted.    
5.2 Discussion of experimental results for the Candida species 
5.2.1    Kirby-Bauer Disk Diffusion Method 
The zones of inhibition for the H. canadensis Ø against emerging 
pathogenic Candida strains, as shown in Table 4.9, demonstrated that the 
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tincture effectively prevented the growth of C. lusitaniae (23 mm),  
C. parapsilosis (35 mm) and C. rugosa (17 mm). The zone of inhibition for 
C. guilliermondii was intermediate, with a zone measuring 11 mm.  
C. inconspicua/Lambica growth was not inhibited by the tincture, with a 
zone of 6 mm; thus, demonstrating resistance.   
C. officinalis Ø did not produce as prominent results as H. canadensis Ø, 
with an average of 10 mm on both C. lusitaniae and C. parapsilosis, showing 
intermediate inhibition of growth. The zones of inhibition for the  
C. guilliermondii, C. inconspicua/Lambica and C. rugosa were below 10 
mm; thus, indicating the minimal inhibitory effects of the C. officinalis Ø. 
 
The complex of H. canadensis Ø and C. officinalis Ø had a zone of inhibition 
of 19 mm for C. lusitaniae, 35 mm for C. parapsilosis, and 17 mm for 
 C. rugosa, which is indicative of sensitivity of these strains to the tincture 
complex. However, C. guilliermondii and C. inconspicua/Lambica displayed 
8 mm and 6 mm zones of inhibition respectively; thus, showing 
intermediate-resistance effects to the tincture complex. Interestingly a 
holistic view reveals that C. inconspicua/Lambica showed resistance to all 
treatments, namely the tinctures, ethanol concentrations and Fluconazole 
control. This strain has been occurring more frequently in human samples 
and is known to be resistant to Fluconazole. As an emerging yeast pathogen 
causing invasive infections, it is vital to find alternative or combination 
treatments (Guitard et al., 2013).       
 The C. parapsilosis and C. lusitaniae showed intermediate resistance with 
an average of 9 mm for all ethanol concentrations. Fluconazole produced a 
large zone of inhibition on C. lusitaniae (36 mm) and C. parapsilosis (47 
mm), which indicates the sensitivity of all the Candida strains to this anti-
fungal, with the exception of C. inconspicua/Lambica, which is inherently 
resistant to Fluconazole. Even though the anti-fungal showed a greater 
zone of inhibition, the results for the H. canadensis Ø, and the H. 
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canadensis and C. officinalis Ø complex are also positive. C. officinalis Ø 
only showed minimum growth inhibition on all Candida spp., with an 
average of 10 mm, which was less or the same as the ethanol concentration 
growths with averages of between 9 and 10 mm. 
5.2.2    Microdilution method 
The Microdilution method was also used to test the effects of the tinctures 
on the other Candida spp., and a reduction in the corrected absorbance 
reading highlighted by a negative value or a value less than the yeast 
absorbance value indicated inhibition of yeast growth.  
5.2.2.1    C. lusitaniae 
The results of C. lusitaniae show that H. canadensis Ø showed fungal 
inhibition at the first well (2x dilution) with an OD reading of -0.94 nm. The 
untreated diluted yeast cells had an OD reading of 0.48 nm; thus, the 
inhibitory effect of H. canadensis Ø is noted by the extreme OD reduction. 
The inhibition was seen for all dilutions, thereafter, confirming the 
effectiveness of H. canadensis Ø against C. lusitaniae.       
The MIC readings for C. officinalis Ø confirmed the inhibition of yeast growth 
for the dilution range by the yeast cells OD reading of 0.48 nm, compared 
to C. officinalis Ø in well one (2x dilution) with an OD value of 0.14 nm.  
The combination of H. canadensis Ø and C. officinalis Ø complex 
demonstrated the lowest OD value of -0.40 nm of all the tinctures tested. 
However, the OD value increased to -0.00nm at the second well (4x 
dilution); thereafter the values increased to 0.08nm, until 0.41 nm at the last 
well. Even though the values increased with the dilutions, the values were 
still below the yeast value, thus confirming inhibition.   
The MIC values for the ethanol controls were 0.27 nm for 66% and 70% 
ethanol, and 0.26 nm for the 68% ethanol. This data showed that the ethanol 
had some level of inhibition against C. lusitaniae. The inhibitory effect of the 
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ethanol controls ended in the second well, and thereafter had no effect on 
the strain; this was noted as the values increased in the subsequent wells.  
The Fluconazole 25mcg had an OD value of 0.16 nm at the highest 
concentration, with an increasing OD value as the anti-fungal was diluted. 
The most diluted Fluconazole concentration had an OD of 0.42 nm, while 
the yeast had an OD value of 0.41 nm. The value was indicative of the 
reduced inhibitory effect of Fluconazole against C. lusitaniae when diluted 
64-fold. The value increased as the dilutions increased, and Fluconazole 
stopped inhibition at the 16-fold dilution with an OD reading of 0.38 nm. This 
reading was higher than the yeast reading of 0.33 nm, which showed no 
inhibitory effects. 
5.2.2.2    C. parapsilosis 
The results of C. parapsilosis demonstrated that H. canadensis Ø showed 
fungal inhibition at the first well (2x dilution) with an OD reading of -0.68 nm, 
which was the lowest value from all the tinctures tested. The untreated 
diluted yeast cells had an OD reading of 0.46 nm; thus, the inhibitory effect 
of H. canadensis Ø is observed by the severe OD reduction. The inhibition 
was seen for all dilutions, thereafter, confirming the effectiveness of  
H. canadensis Ø against C. parapsilosis.       
The MIC readings for C. officinalis Ø corroborated the inhibition of yeast 
growth for the dilution range by the yeast cells OD reading of 0.46 nm, 
compared to the most concentrated C. officinalis Ø in well one (2x dilution), 
with an OD value of 0.03 nm.  
The combination of H. canadensis Ø and C. officinalis Ø had an OD value 
of -0.85 nm. However, the OD value increased to -0.05nm at the second 
well (4x dilution), and thereafter the values increased to 0.30 nm at the last 
well. Even though the values increased with the dilutions, the values were 
still below the yeast values which confirms the effectiveness of the complex 
against C. parapsilosis. 
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The MIC values for the ethanol controls were 0.35 nm for 66% and 68% 
ethanol, and 0.28 nm for the 70% ethanol. This data showed that the ethanol 
displayed inhibition against C. parapsilosis until the 32-fold dilution, which 
surprisingly was the same as the Fluconazole 25mcg, which had an OD 
value of 0.36 nm. The most diluted Fluconazole concentration had an OD 
of 0.46 nm, while the yeast had an OD value of 0.43 nm. The value was 
indicative of the reduced inhibitory effect of Fluconazole against  
C. parapsilosis when diluted 64-fold.  
The results of C. parapsilosis demonstrated that H. canadensis Ø showed 
fungal inhibition at the first well (2x dilution) with an OD reading of -0.68 nm, 
which was the lowest value for all the tinctures tested. The untreated diluted 
yeast cells had an OD reading of 0.46 nm, thus the inhibitory effect of  
H. canadensis Ø is observed by the severe OD reduction. The inhibition 
was seen for all dilutions, thereafter, confirming the effectiveness of  
H. canadensis Ø against C. parapsilosis.       
The MIC readings for C. officinalis Ø showed the inhibition of yeast growth 
for the dilution range, with a yeast cell OD reading of 0.46 nm in comparison 
to C. officinalis Ø (2x dilution), with an OD value of 0.03 nm.  
The combination of H. canadensis Ø and C. officinalis Ø had an OD value 
of -0.85 nm. However, the OD value increased to -0.05nm at the second 
well (4x dilution); thereafter the values increased to 0.04nm until 0.30 nm at 
the last well. Even though the values increased with the dilutions, they were 
still below the yeast values, which confirms the effectiveness of the complex 
against C. parapsilosis. 
The MIC values for the ethanol controls were 0.35 nm for 66% and 68% 
ethanol, and 0.28 nm for the 70% ethanol. This data showed that the ethanol 
displayed inhibition against C. parapsilosis until the 32-fold dilution, which 
surprisingly was the same as the Fluconazole 25mcg which had an OD 
value of 0.36 nm. The most diluted Fluconazole concentration had an OD 
of 0.46 nm compared to the yeast OD value of 0.43 nm. The value was 
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indicative of the reduced inhibitory effect of Fluconazole against  
C. parapsilosis when diluted 64-fold.  
5.2.2.3    C. rugosa, C. guilliermondii and C. inconspicua/Lambica 
The results of C. rugosa, C. guilliermondii and C. inconspicua/Lambica 
demonstrated that H. canadensis Ø showed fungal inhibition at the first well 
(2x dilution) with an OD reading of 0.06 nm, -0.83 nm, and 0.57 nm, 
respectively. The untreated diluted yeast cells had an OD reading of 0.43 
nm, 0.61 nm, and 1.29 nm; therefore, the inhibitory effect of H. canadensis 
Ø is observed by the OD reduction. The inhibition was seen for all dilutions, 
thereafter, confirming the effectiveness of H. canadensis Ø against  
C. rugosa, C. guilliermondii and C. inconspicua/Lambica.       
The MIC readings for C. officinalis Ø confirmed the inhibition of yeast growth 
for C. rugosa, C. guilliermondii for all the wells tested, however for  
C. inconspicua/Lambica there was no inhibition in the first well with an OD 
reading of 1.37 nm, whilst the yeast cells had an OD reading of 1.29 nm. 
Inhibition was noted for C. officinalis Ø in well two (4x dilution) with an OD 
value of 1.09 nm; this continued until the 64-fold dilution where inhibition 
stopped with the increase in dilution. 
The complex of H. canadensis Ø and C. officinalis Ø had OD values of 0.12 
nm, -0.26 nm, and 1.04 nm, respectively. The OD value for C. rugosa 
decreased to -0.03 nm at the second well (4x dilution); thereafter the values 
increased to 0.08nm until 0.28 nm at the last well. Even though the values 
increased with the dilutions, they were still below the yeast values, which 
confirms the effectiveness of the complex against C. rugosa. The results of 
C. guilliermondii showed that the values increased after the first well until 
the last well where inhibition stopped, with an OD reading of 0.64 nm. C. 
inconspicua/Lambica displayed inhibition until the 16-fold dilution, and 




The values of the control groups are discussed in the paragraphs below: 
The MIC values for the ethanol controls of C. rugosa were 0.05 nm for 66% 
ethanol, 0.10 nm for 68% ethanol, and 0.13 nm for the 70% ethanol. This 
data showed that the ethanol displayed inhibition against C. rugosa until the 
8-fold dilution; however, the 70% ethanol inhibition started at the 16-fold 
dilution and ended at the 64-fold dilution. The Fluconazole 25mcg had an 
OD value of 0.18 nm. The most diluted Fluconazole concentration had an 
OD of 0.42 nm, compared to the yeast OD value of 0.37 nm, and reduced 
inhibition at the 8x fold dilution, indicating that it was not effective on  
C. rugosa with the increased dilutions. 
The MIC values for the ethanol control groups of C. guilliermondii were 0.14 
nm for 66%, 0.15 nm for 68% ethanol, and 0.19 nm for the 70% ethanol. 
This data showed that all the ethanol concentrations displayed inhibition 
against C. guilliermondii, until the 32-fold dilution. The Fluconazole 25mcg 
had an OD value of 0.18, compared to the yeast OD value of 0.61 nm. The 
most diluted Fluconazole concentration had an OD value of 0.59 nm, which 
was equal to the yeast OD value. Fluconazole only showed inhibition at the 
32-fold dilution, whilst the other wells showed that it was not effective on  
C. guilliermondii. This was inconsistent with the other strain readings. 
The MIC values for the ethanol controls of C. inconspicua/Lambica were 
0.48 nm for 66%, 0.86 nm for 68% ethanol, and 1.02 nm for the 70% 
ethanol. This data showed that the 66% concentration had inhibition at the 
32-fold dilution, whilst the 68% ethanol showed inhibition at the 4-fold 
dilution and16-fold dilution, while the other dilutions had no effect. The 70% 
ethanol showed inhibition until the 4-fold dilution, and thereafter had no 
effect; this was also inconsistent with other readings. The Fluconazole 
25mcg had an OD value of 1.19 nm at the first well (2x dilution). The most 
diluted Fluconazole concentration had an OD value of 0.59 nm, which was 
less than the yeast OD value of 1.29 nm. Fluconazole only showed inhibition 
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at the 2-fold dilution, whilst the other wells showed that it was not effective 
on C. inconspicua/Lambica. 
5.2.3    Minimum Fungicidal Concentration (MFC) 
This method was used to check whether the tinctures, ethanol 
concentrations, and anti-fungal compound used in the 96 wells were 
fungicidal or fungistatic against C. lusitaniae, C. parapsilosis, C. rugosa,  
C. guilliermondii and C. inconspicua/Lambica. From the MFC analysis, it 
was noted that all the tinctures had a fungistatic (suppressed growth) effect 
instead of fungicidal (killed) effect. The recovery of the yeast cells, when 
given nutrients, enabled them to grow and flourish after the incubation 
period, which confirmed the fungistatic mechanism of the tinctures. To 
determine the fungicidal levels of the tinctures, further dose experiments 
need to be conducted.    
5.4 Related research and discussion of results 
5.4.1    H. canadensis Ø 
H. canadensis Ø is a known anti-fungal, with berberine being its most active 
component (Mandal et al. 2020). In this study, H. canadensis Ø was shown 
to inhibit the growth of C. albicans and the other Candida spp., exhibiting 
fungistatic properties. Overall, H. canadensis Ø was the most effective of 
the tinctures against these strains. While Fluconazole was shown to 
outperform the tincture, this study provides evidence that H. canadensis Ø 
may be an effective alternative anti-fungal in the treatment of  
C. albicans and the other Candida spp. This result is supported by a study 
carried out by Budree (2004), which showed that H. canadensis Ø inhibited 
the growth of C. albicans in vitro using the Kirby-Bauer Disk Diffusion 
method. Research on H. canadensis Ø as a homeopathic preparation is 




Wei et al. (2011) that demonstrated how the isolated alkaloid berberine 
inhibited the growth of various Candida species, including C. albicans in 
vitro using the MIC method. Another study by da Silva et al. (2016) 
evaluated the anti-fungal effect of berberine against Fluconazole-resistant 
Candida strains and biofilm formation of Candida spp., using the broth 
dilution method. The results confirmed that berberine inhibited the growth 
of Fluconazole resistant Candida strains and reduced the capability of 
biofilm formation. The study by Li et al. (2018) showed the synergism 
between Fluconazole and berberine against Fluconazole-resistant  
C. albicans in vitro. By exposing the yeast to different concentrations of 
Fluconazole and berberine using the time kill curve assay, it was identified 
that Fluconazole was more effective when the berberine concentration was 
increased.  
5.4.2    C. officinalis Ø 
C. officinalis Ø is known for its anti-fungal, anti-inflammatory, and anti-
bacterial properties, and has previously been shown to be effective as an 
anti-fungal treatment (Faustino et al., 2018). In this study, C. officinalis Ø 
was shown to inhibit the growth of C. albicans and the other Candida spp. 
with fungistatic effects. However, it was not as effective as the  
H. canadensis Ø, or as Fluconazole, as it only showed intermediate effects 
towards the various strains. According to the MIC method, however,  
C. officinalis Ø inhibited C. albicans from the first well with a 2- fold dilution. 
These results show that the tincture performs better in the broth solution 
method than the diffusion method, however the reason for this is unknown. 
It can be concluded that C. officinalis Ø may potentially be used as an anti-
fungal against most Candida strains, however further testing is required. 
Once again, there is very limited research on the homeopathic preparations 
of this medicinal plant. De Klerk (1998) performed an in vitro study which 
showed that D1 and D3 potencies of C. officinalis were effective in inhibiting 
C. albicans, using the disk diffusion method. Other studies relate to the 
herbal preparations of this plant. Efstratiou et al. (2012) performed an in 
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vitro disk diffusion study on the antimicrobial activity of the petal extracts of 
C. officinalis against gram positive, gram negative and fungal clinical 
pathogens; the results showed that the ethanol and methanol extracts had 
outstanding anti-fungal activity against C. albicans and C. parapsilosis. 
These results support a previous research study done by Verma et al. 
(2018), where the anti-fungal effects of floral and leaf extracts of  
C. officinalis were tested against various strains of Candida spp. in vitro 
which showed that both extracts were effective while the oils of the flower 
were effective against Candida spp. 
The results in this study were evident for the other Candida spp. strains that 
were tested, where it inhibited the yeast from the first well with a 2- fold 
dilution; however, the C. inconspicua/Lambica strain showed resistance in 
the first well. 
The complex of H. canadensis Ø and C. officinalis Ø displayed anti-fungal 
effects in both methods that were tested. There are currently no studies 
showing the effects of both these tinctures together however the synergistic 
effects of herbal medicine as per a review by Ma et al. (2009), shows that if 
two herbal ingredients mutually  enhance the effect of each other, or the 
one increases the effect of the other, then they can be effective as 
treatments in combination. In order to understand the standardisation of 
homeopathic tinctures and the homeopathic methods, continuous research 
should be done, which could be used to advance therapeutic outcomes and 
enable more effective treatment protocols. 
5.4.3    Ethanol concentrations 
Ethanol has the ability to kill off certain microbes; therefore, it is frequently 
used as an antiseptic to sterilise equipment and prevent infection, and can 
be fungicidal (Elzain et al., 2019). In this study, ethanol was used as a 
control, and it revealed that the ethanol concentrations tested on C. albicans 
and other Candida spp. had intermediate effects; however, in the MIC, the 
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66% ethanol concentration inhibited the yeast until the 16-fold dilution, the 
68% until the 4-fold dilution, whilst the 70% inhibited the yeast in all the 
wells, up to the 64-fold dilution; however, the Fluconazole still outperformed 
this result. This is supported in a study by Peters et al. (2012) who used the 
dose and time method to check which concentration of alcohol was most 
effective in the killing of both monomicrobial and polymicrobial biofilms 
formed on surfaces. The results showed that four hours was sufficient to kill 
C. albicans in 30% ethanol, and this was confirmed by a study done by 
Rane et al. (2012). 
5.4.4    Fluconazole 
Fluconazole is an anti-fungal agent that is used effectively to treat most 
fungal infections; however, prolonged use can result in the development of 
resistance (Lu et al., 2017). Krishnasamy et al. (2018) showed that 
Fluconazole is a commonly used drug that acts as a fungistatic drug rather 
than fungicidal drug, which increases its risk for drug resistance. It was also 
used chronically to treat infections related to Candida species; however, an 
understanding of the molecular mechanisms of the drug is required to avoid 
resistance. In this study, Fluconazole outperformed the H. canadensis Ø, 
the C. officinalis Ø, the H. canadensis and C. officinalis Ø complex, as well 
as the 66%, 68% and 70% ethanol samples in the Kirby-Bauer method. In 
the Microdilution method, the H. canadensis and C. officinalis Ø complex 
outperformed all of the other treatments tested, but Fluconazole still 
inhibited the yeast until the 32-fold dilution. These results are confirmed in 
the study by Moosa et al. (2004), which showed that Fluconazole 150mcg 
in one dose had fungicidal activity in in vitro settings,  to eliminate  
C. albicans. 
5.5 Limitations of this study 
It is essential to understand the limitations of this study in the interpretation 
of the results found.  
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Limitations of the study include:  
• Studies on the effects of specific doses of H. canadensis Ø,  
C. officinalis Ø, and H. canadensis and C. officinalis Ø complex were 
not included in the research, which could have provided important 
insight in determining which dosage would be more effective in killing 
the yeast. 
• H. canadensis Ø and C. officinalis Ø are frequently prescribed in 
higher potencies in clinical practice; however, this study did not 
evaluate the effects of ultra-high dilutions of these remedies. 
•  This study was carried out in vitro; therefore, the effects of the 
therapy in vivo were not ascertained.  
• Time-kill studies could be used to test the effects of the  
H. canadensis Ø, the C. officinalis Ø, and the H. canadensis and  













6. CONCLUSION & RECOMMENDATIONS 
6.1 Conclusion 
The aim of this study was to test the effectiveness of H. canadensis and  
C. officinalis Ø complex as an anti-fungal against C. albicans and other 
Candida spp., using the Kirby-Bauer Disk Diffusion and Microdilution 
methods. 
The results demonstrated that the H. canadensis and C. officinalis Ø 
complex inhibited the growth of C. albicans and other Candida spp., which 
was confirmed by the Kirby-Bauer Disk Diffusion and Microdilution methods. 
The H. canadensis Ø and C. officinalis Ø on their own inhibited the growth 
of C. albicans in varying degrees; however, the H. canadensis and the  
C. officinalis Ø complex displayed better anti-microbial properties than the 
C. officinalis Ø on its own. Fluconazole, however, performed significantly 
better than the tinctures. 
The minimum fungicidal method was used to check if the treatments were 
fungistatic or fungicidal, and overall, the Ø’s were fungistatic. Regardless of 
the lower concentration of active ingredients found in homeopathic Ø’s 
compared to herbal extract preparations, an anti-fungal effect was 
observed. 
It was hypothesised that the homeopathic Ø’s of H. canadensis and  
C. officinalis, used in combination, will show antimicrobial action against  
C. albicans and other Candida spp. This was supported and confirmed by 
this study. 
In conclusion, the H. canadensis and C. officinalis Ø complex did show 
inhibitory effects against C. albicans and other Candida spp., and it was 
confirmed to be a fungistatic effect, however the C. inconspicua/Lambica 
strain showed resistance. This study has expanded our knowledge of the 
antimicrobial effects of H. canadensis Ø and C. officinalis Ø both on their 
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own, and as a complex in vitro. It needs to be ensured that, when using 
homeopathic Ø’s, that the correct dose required for it to be fungicidal be 
determined. Combined effects of the tinctures with standard anti-fungal 
treatment can also be explored in future studies.   
6.2 Recommendations 
Further research is recommended to confirm the results of this study: 
• Studies on the effects of H. canadensis Ø, the C. officinalis Ø, and 
the H. canadensis and C. officinalis Ø complex at specific doses 
should be done to ascertain at which dose the tinctures are most 
effective in killing the yeast. 
• H. canadensis and C. officinalis Ø complex in homeopathic potency 
can be tested to determine its anti-fungal effects. 
• In vivo tests and clinical trials should be done on the H. canadensis 
and C. officinalis Ø complex, to check how effective it is. 
• Time-kill studies should be done in the lab to establish if the   
H. canadensis and C. officinalis Ø complex, and the Ø’s on their own, 
are only fungistatic or fungicidal. 
• Further research, in investigating the combined effects of  
H. canadensis Ø and Fluconazole. 
• The use of diluted ethanol as a solvent for the tinctures may be more 
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The mother tinctures (ø ) of Calendula officinalis and Hydrastis canadensis 
will be made using HAB method 3A and HAB method 4A, respectively 
(Deutscher Apotheker Verlag, 2013). 
HAB 3A method: Calendula officinalis 
• Plants or parts of plants are chopped up 
• A sample is used to detect loss on drying 
• Instantly add half the amount of 86% alcohol to the chopped plant 
elements 
• Store in a well- sealed container at a temperature not surpassing 
20°C 
• Calculate the amount of 86% ethanol (m/m) required for the mass 
of the plant 
• Leave the mixture to stand for a minimum of 10 days at a 
temperature not surpassing 20°C swirling from time to time 
• Express and filter 
• Use 62% ethanol to adjust to any concentration as required in the 
monograph 
HAB 4A method : Hydrastis canadensis 
• Tinctures are made from dried plants or parts thereof and are 
manufactured using the percolation or maceration method. 
• 1 part of the drug to 10 parts of 62% ethanol , the mixture is left to 
stand for a minimum of 10 days at a temperature not surpassing 
20°C 
• Filter 
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